ImmunityBio investors who purchased stock between January 19, 2026 and March 25, 2026 are being urged to participate in a new securities class action lawsuit filed against the company and its chair, Patrick Soon-Shiong. Three major law firms—Robbins Geller Rudman & Dowd LLP, Rosen Law Firm, and Pomerantz LLP—are actively seeking investors to join the litigation, which alleges that ImmunityBio made materially false and misleading statements about the capabilities of its cancer immunotherapy drug, Anktiva. The lawsuit was triggered by an FDA warning letter issued on March 24, 2026, in which the agency stated that ImmunityBio’s promotional communications created a misleading impression that Anktiva could cure and prevent all types of cancer—claims the company had not substantiated through clinical evidence. Following the FDA warning letter disclosure, ImmunityBio’s stock price fell 21%, wiping out millions in investor value.
5 million settlement ImmunityBio reached in 2025. For investors in ImmunityBio stock, participation in this lawsuit offers a potential path to recover losses without bearing the burden of individual litigation. The lead plaintiff deadline—the cutoff for investors to apply to be named as the main plaintiff in the case—is May 26, 2026. Missing this deadline does not automatically exclude you from the class action, but it does prevent you from taking a leadership role in the litigation. Understanding the details of what happened, who is liable, and what timelines apply is critical for making an informed decision about whether to participate.
Table of Contents
- What Does the ImmunityBio Lawsuit Allege?
- How Did the FDA Warning Letter Affect Investors?
- Understanding the Stock Price Impact and Investor Losses
- What Are Your Options as an Affected Investor?
- Comparing This Lawsuit to ImmunityBio’s Previous Settlement
- What Happens Next in the Litigation Process?
- What This Means for the Future of Biotech Company Communications
What Does the ImmunityBio Lawsuit Allege?
The class action lawsuit focuses on statements immunitybio made about Anktiva’s clinical potential and regulatory prospects. According to the lawsuit, the company and Soon-Shiong made representations suggesting Anktiva was a near-certain path to FDA approval and would be transformative for cancer treatment—representations not supported by the actual data. In reality, Anktiva had not completed the clinical trials necessary to support broad approval claims, and the drug faced significant regulatory uncertainty. The FDA’s March 24 warning letter provided the first public confirmation that regulators had serious concerns about how ImmunityBio was marketing the drug.
The agency specifically cited promotional materials that went far beyond what the clinical evidence could support, essentially charging the company with misleading patients and healthcare providers about what Anktiva could and could not do. This pattern of overstated claims is not ImmunityBio’s first regulatory stumble. The company previously settled a securities class action in June 2025 (covering the 2021-2023 period) for $10.5 million, in which it faced similar allegations about false statements regarding manufacturing capabilities, FDA compliance, and the likelihood of Anktiva approval. That settlement compensated investors at approximately $0.09 per damaged share. The current lawsuit covers a more recent period and a different set of misrepresentations, but the fact that ImmunityBio faced serious accusations twice in five years suggests a pattern in how the company communicated with investors.
How Did the FDA Warning Letter Affect Investors?
The FDA warning letter dated March 24, 2026, was a watershed moment for ImmunityBio investors. Before the letter became public, the stock was trading at a certain level based on investor assumptions about Anktiva’s regulatory pathway. The moment the warning letter disclosed—revealing that the FDA considered ImmunityBio’s marketing claims to be misleading—the market repriced the stock downward by 21%. This sharp decline reflects investors suddenly understanding that Anktiva was not on the clear path to approval that the company had suggested. In securities law terms, this is the harm that class actions are designed to address: investors who bought stock based on misleading statements about a drug’s regulatory prospects suffered quantifiable losses when the truth came out.
However, not all investors who owned ImmunityBio stock during this period will be eligible to recover. The lawsuit covers only the period from January 19, 2026 (when the lawsuit alleges the misleading statements began or intensified) through March 25, 2026 (the date class period closes). If you purchased shares before January 19, 2026 and held them through the period, you are not part of this class, though you may be part of the earlier settled case. If you purchased shares for the first time after March 25, 2026, you are also outside the class period. The key is when you held shares during the deceptive period; investors who bought after March 24 (when the warning letter came out) were not misled by the same statements and thus have no claim.
Understanding the Stock Price Impact and Investor Losses
ImmunityBio’s 21% stock price drop following the FDA warning letter announcement is significant but not unusual in the context of clinical-stage biotech companies. When regulatory risk crystallizes—when an agency like the FDA publicly signals problems—investors immediately reassess the company’s valuation. For a company whose primary asset is a single drug candidate in early-stage testing, a negative FDA signal can erase substantial shareholder value. Consider an investor who bought $10,000 worth of ImmunityBio stock in early March 2026 based on the company’s statements about Anktiva’s potential. By late March, that same position could have been worth approximately $7,900, a loss of $2,100. Multiply this across hundreds or thousands of investors, and the total damages approach tens of millions of dollars.
The timing of the disclosure also matters legally. The FDA did not suddenly discover these marketing problems on March 24—regulatory agencies review promotional materials continuously. What the public warning letter represented was the moment when investors learned what the FDA already knew. The lawsuit’s premise is that ImmunityBio should have disclosed the regulatory concerns earlier or adjusted its marketing claims sooner. If the company was aware (or should have been aware) that its Anktiva marketing was problematic, failing to disclose that knowledge while continuing to make bullish statements constitutes securities fraud. The question for the court will be what ImmunityBio knew and when it knew it.
What Are Your Options as an Affected Investor?
As an ImmunityBio investor during the class period (January 19 – March 25, 2026), you have three main paths forward. First, you can do nothing and wait to be included in the class action settlement (should one occur), which would make you an unnamed class member. Settlement distributions to unnamed class members are typically handled through a claims process after the settlement is finalized. Second, you can apply to be named lead plaintiff by the deadline of May 26, 2026. Lead plaintiffs have greater visibility, are typically updated by counsel throughout the litigation, and their names appear on court documents—though they also may face greater scrutiny and time commitments. Third, you can opt out of the class action, though this is rarely advisable in securities litigation because opting out means you waive any right to recover from a settlement or judgment, and pursuing an individual claim against a company like ImmunityBio is prohibitively expensive.
The lead plaintiff role has a practical benefit beyond recognition: lead plaintiffs are often named first in settlement distributions or updates. Additionally, some class action agreements provide nominal compensation or recognition bonuses to lead plaintiffs, though this varies by case. However, being lead plaintiff is not required to receive your share of any settlement. Most investors in class actions remain unnamed and still recover proportionally to their losses. The law firms involved—Robbins Geller, Rosen, and Pomerantz—are experienced class action practitioners who will move the case forward regardless of who the lead plaintiff is. If you want to participate but have no interest in being the lead plaintiff, simply staying in the class and following the eventual settlement notification is sufficient.
Comparing This Lawsuit to ImmunityBio’s Previous Settlement
ImmunityBio’s prior settlement in 2025 provides a useful reference point for understanding what might happen in the current case. The 2021-2023 settlement involved a $10.5 million payment to resolve allegations of false statements about manufacturing capabilities, FDA compliance, and Anktiva approval odds. That settlement was final-approved in June 2025, meaning investors who qualified (those who held stock during March 10, 2021 – May 10, 2023) could file claims and receive payments. The per-share recovery was approximately $0.09 for each share damaged during the class period. That means an investor with 1,000 shares could have recovered around $90, though actual recoveries depended on whether their purchase and sale prices matched the calculation model used. The current lawsuit differs in several respects that could affect its value.
First, the class period is much shorter (roughly two months versus two years), which typically means a smaller population of affected investors, potentially leading to higher per-share recoveries if the damages are similar or substantial. Second, the specific facts are clearer and more dramatic in the new case: the FDA warning letter provides a precise, public validation of investor harm. In the 2021-2023 case, ImmunityBio denied wrongdoing but settled to avoid litigation costs—a common defensive posture. Here, the FDA itself has endorsed the plaintiffs’ core allegation (that statements were misleading). Third, the new lawsuit names Patrick Soon-Shiong as a co-defendant, adding individual liability and potentially more incentive for a quick settlement to avoid personal liability discovery. However, timing also matters: the new case is only weeks old, while the 2021-2023 case took multiple years to resolve. Investors should not expect a quick settlement in the current case.
What Happens Next in the Litigation Process?
Class action securities litigation follows a predictable timeline. The case is likely filed in federal court (or consolidated into federal court if multiple suits were filed, which appears to be the case here given that three major firms are pursuing it). Over the coming weeks and months, the defendants will file motions to dismiss, arguing that the complaint fails to state a legal claim. If the court allows the case to proceed past the motion to dismiss phase, the parties typically enter a period of discovery—the exchange of documents and evidence. Discovery in securities cases can be extensive, potentially reaching into thousands of pages of company emails, board meeting minutes, communications with the FDA, and internal discussions about Anktiva’s regulatory status.
During discovery, the key question will be what ImmunityBio knew about Anktiva’s regulatory reception before the public FDA warning. If internal emails show company executives discussing FDA concerns about marketing, or if board materials reference regulatory skepticism, those documents strengthen the plaintiffs’ case significantly. If, conversely, the company believed its statements were accurate and had no reason to think the FDA would issue a warning, the defense is stronger. After discovery, the case typically moves toward settlement negotiations, often mediated by a retired judge. Most class action securities cases settle rather than go to trial, with settlements ranging from modest (a few million) to substantial (tens of millions) depending on the strength of evidence and the defendants’ desire to avoid trial risk. The law firms involved in the ImmunityBio case have the resources and track record to litigate seriously, which may encourage settlement.
What This Means for the Future of Biotech Company Communications
The ImmunityBio litigation touches on a broader issue in biotech and pharmaceutical company investor communications: the tension between promoting promising research and making legally defensible statements. Biotech companies need investor support and are naturally eager to highlight their most promising candidates. However, securities law requires that statements about regulatory prospects be based on current facts and not on speculation about what the FDA might do. The FDA warning letter suggests that ImmunityBio crossed that line, making claims about Anktiva’s curative and preventive potential that the clinical evidence and regulatory discussions did not support. Going forward, other companies will notice that making overstated claims about a drug’s potential—even if well-intentioned—can trigger regulatory pushback, investor litigation, and stock price collapse.
This case also highlights the importance of transparency between companies and regulators. If ImmunityBio had acknowledged in its investor disclosures that the FDA had concerns about its marketing messaging, investors would have known the regulatory risk was higher and could have priced that in. Instead, the surprise of the FDA warning letter created a sharp, painful repricing. For biotech investors, this serves as a reminder that regulatory agencies like the FDA are independent actors; they don’t validate company claims just because a company has made them. A careful reading of SEC filings and an understanding of the difference between clinical promise and regulatory approval are essential for avoiding these kinds of surprises.